US Patent
US10751349 — Compositions of obeticholic acid and methods of use
Formulation · Assigned to Intercept Pharmaceuticals Inc · Expires 2036-04-26 · 10y remaining
Vulnerability score
25/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects compositions of obeticholic acid with improved stability, dissolution, and/or solubility, and methods of preparing and using them.
USPTO Abstract
The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
Drugs covered by this patent
- Ocaliva (OBETICHOLIC ACID) · Intercept Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.